BICX BioCorrx Inc

BioCorRx to Present at the H.C. Wainwright 24th Annual Global Investment Conference

BioCorRx to Present at the H.C. Wainwright 24th Annual Global Investment Conference

ANAHEIM, CA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- via – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, CEO, CFO, and Director of BioCorRx, will be presenting at the H.C. Wainwright 24th Annual Global Investment Conference which is being held September 12th - 14th, 2022. The event will include virtual participation as well as in-person participation at the Lotte New York Palace Hotel in New York City.

The Company’s presentation will be available on-demand to registered attendees via the conference platform beginning Monday, September 12, 2022, at 7:00 AM Eastern Time. Management will also be participating in one-on-one meetings with qualified members of the investment community throughout the conference.

About BioCorRx

BioCorRx Inc. (OTCQB: BICX) is an addiction treatment solutions company offering a unique approach to the treatment of substance use and other related disorders. Beat Addiction Recovery is a substance use disorder recovery program that typically includes BioCorRx's proprietary Cognitive Behavioral Therapy (CBT) modules along with peer support via mobile app along with medication prescribed by an independent treating physician under their discretion. The UnCraveRx® Weight Loss Program is also a medication assisted weight loss program that includes access to concierge on-demand wellness specialists: nutritionists, fitness experts and personal support from behavioral experts; please visit for more information on UnCraveRx®. The Company also controls BioCorRx Pharmaceuticals, a clinical stage drug development subsidiary currently seeking FDA approval for BICX104, an implantable naltrexone pellet for treatment of alcohol and opioid use disorders. For more information on BICX and its subsidiary pipeline, please visit .

Safe Harbor Statement

The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown. risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

BioCorRx Inc.



714-462-4880

Investor Relations:

Crescendo Communications, LLC

212- 671-1020 x304

Media Contact

PhillComm Global

al

704-942-1557



EN
06/09/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BioCorrx Inc

 PRESS RELEASE

BioCorRx Reports Business Update for the Second Quarter of 2024

BioCorRx Reports Business Update for the Second Quarter of 2024 ANAHEIM, CA, Aug. 15, 2024 (GLOBE NEWSWIRE) -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended June 30, 2024, and reported on recent corporate developments. Additionally, BioCorRx Inc. announces the expansion of its intellectual property portfolio with a new international patent awarded from Israel for the treatment of weight loss. This patent covers the use of a subcut...

 PRESS RELEASE

BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to...

BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia ANAHEIM, CA, April 03, 2024 (GLOBE NEWSWIRE) -- via --  BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer of innovative treatment programs for substance use and related disorders, today announced that its subsidiary BioCorRx Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, has been granted a new patent by the United States Patent and Trademark Office (USPTO). The USPTO has issued U.S. Patent No. 11,793,801 entitled, “Treatment of Pain and Neurologi...

 PRESS RELEASE

BioCorRx Reports Business Update for 2023

BioCorRx Reports Business Update for 2023 ANAHEIM, CA, April 02, 2024 (GLOBE NEWSWIRE) -- via — BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the year ended December 31, 2023, and reported on recent corporate developments. Lourdes Felix, CEO, CFO, and Director of BioCorRx Inc., commented, “In 2023, we made significant strides in advancing the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet designed for treating opioid ...

 PRESS RELEASE

BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 ...

BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD ANAHEIM, CA, Feb. 28, 2024 (GLOBE NEWSWIRE) -- via – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders, announced that its subsidiary BioCorRx Pharmaceuticals Inc. has been awarded a 3-year grant for approximately $11 million from the National Institute on Drug Abuse (NIDA), part of the National Institut...

 PRESS RELEASE

BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarne...

BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors ANAHEIM, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, announced that its subsidiary BioCorRx Pharmaceuticals Inc., has appointed Kate Beebe DeVarney, Ph.D. to its Board of Directors. Dr. DeVarney spearheaded the development of Probuphine® (buprenorphine implant), the first six-month, subcutaneous implant approved in the United States, Canada, a...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch